Moreover, with the observation that GSK126 could mimic the inhibitory effect of SPRY4 on EZH2 and MDM2, our work indicated that EZH2 might be a direct target of SPRY4 in CRC. This evidence concerns the gene MDM2 and colorectal carcinoma.